Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) [Phase 3]

View source ↗

Summary

This clinical trial update announces a Phase 3 study (EMERGENT TEEN) evaluating KarXT for schizophrenia in adolescents, with recruitment currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Schizophrenia | Phase 3 | Status: RECRUITING